Skip to content
Psychedelic Alpha· Josh·· 4 days agoAI score78

Helus Pharma reports positive topline results from first phase 3 trial of HLP003 in major depressive disorder

Breaking: Helus’ Deuterated Psilocin Hits Primary Endpoint in First Phase 3

AI summary

Helus Pharma, formerly Cybin, announced a positive topline readout from its first Phase 3Larger trials meant to confirm a drug's effects and safety, usually needed before a regulator will consider approving it.Open the glossary study of HLP003, a deuterated psilocin analog, for the adjunctive treatment of major depressive disorder (MDD). The trial is part of the company's PARADIGM phase 3 program, which tests HLP003 as an adjunctive treatment in adults who have had an inadequate response. The announcement gives no effect size, adverse eventAny unwanted medical occurrence in a trial participant, whether or not it was caused by the treatment.Open the glossary data or participant numbers.

Key facts

Kind of item
Trial results
Compound
Psilocybin
Condition
Depression
Organisation
Cybin
Trial phase
Phase 3
Source
Psychedelic Alpha (psychedelicalpha.com)
Published
How this summary was made

The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: Psychedelic Alpha · psychedelicalpha.com

Connected to

Kind of item
Trial results
Compound
Psilocybin
Condition
Depression
Organisation
Cybin

Other recent items on these topics